The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

被引：7

作者：

Sarpatwari, Ameet ^{[1
]}

Kesselheim, Aaron S.

机构：

[1] Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA

来源：

PLOS MEDICINE | 2016年 / 13卷 / 02期

关键词：

METAANALYSIS; OUTCOMES; COHORT;

D O I：

10.1371/journal.pmed.1001955

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：6

共 4 条

[1] Brand Loyalty and Generic Entry: Why Do Brand-Name Drug Companies Launch Their Own Generics?
Yunyun Wan
[J]. The Japanese Economic Review, 2018, 69 : 340 - 346
[2] Brand Loyalty and Generic Entry: Why do Brand-Name Drug Companies Launch Their Own Generics?
Wan, Yunyun
[J]. JAPANESE ECONOMIC REVIEW, 2018, 69 (03) : 340 - 346
[3] THE IMPACT OF GENERIC DRUG ENTRY ON MARKET SHARES AND PRICES OF BRAND-NAME DRUGS-EVIDENCE FROM CHINESE PHARMACEUTICAL MARKET
Chen, J.
Tian, Y.
Shi, L. W.
[J]. VALUE IN HEALTH, 2018, 21 : S9 - S9
[4] Benidipine/diltiazemIncreased frequency of vasospastic angina attacks due to switch from brand-name drug to a generic drug: 2 case reports
[J]. Reactions Weekly, 2018, 1703 (1) : 57 - 57

← 1 →